MagSense® Phase 1 Study – HER2 Breast Cancer

An Investigational Study of a Novel Imaging Agent for Nodal Staging of HER2 Breast Cancer

Imagion Biosystems is currently conducting a Phase 1 clinical study of its MagSense® HER2 imaging agent.

The imaging agent is specifically designed for breast cancer patients that test positive for the Human Epidermal Growth Factor Receptor 2 (HER2).

This study aims to show that this new targeted imaging agent is safe and its potential to non-invasively stage breast cancer by detecting if cancer has spread to the lymph nodes.

Details of the study can be found at Australia New Zealand Clinical Trial Registry.

Download the brochure

If you are interested in learning more

Please contact Imagion Biosystems at 1 800 749 262 or